15:36 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sobi grabs Emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501). Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million) in...
22:11 , Jul 20, 2018 |  BC Extra  |  Company News

Sobi grabs emapalumab, anticipates 2018 approval

Swedish Orphan Biovitrum AB (SSE:SOBI) received exclusive, worldwide rights from Novimmune S.A. (Plan-les-Ouates, Switzerland) to hematology candidate emapalumab (NI-0501). Novimmune will receive SEK450 million ($50.8 million) up front in cash, plus SEK3.6 billion ($406.5 million) in...
18:33 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Tricida, Translate Bio, Forty Seven and Entera price IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance on June 28, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each...
05:15 , Jun 28, 2018 |  BC Extra  |  Financial News

Tricida gains, others dip after upsized IPOs

Among three well-funded biotechs that priced IPOs, Tricida Inc. (NASDAQ:TCDA) had by far the best first-day performance Thursday, posting a 37% gain, while Translate Bio Inc. (NASDAQ:TBIO) and Forty Seven Inc. (NASDAQ:FTSV) each lost ground. All...
20:02 , Jun 20, 2018 |  BC Extra  |  Company News

TG, Novimmune developing CD47/CD19 bispecific

TG Therapeutics Inc. (NASDAQ:TGTX) partnered with Novimmune S.A. (Plan-les-Ouates, Switzerland) to develop Novimmune’s TG-1801 (formerly NI-1701). The companies plan to begin clinical testing of the candidate this year or early next year, with a focus...
15:32 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Forty Seven reports partial responses in ovarian cancer patients treated with Hu5F9-G4

Forty Seven Inc. (Menlo Park, Calif.) reported data from a Phase I trial showing that Hu5F9-G4 as monotherapy led to confirmed partial responses in two heavily pretreated patients with ovarian cancer. One of the patients...
18:24 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Forty Seven reports Phase Ib data for Hu5F9-G4 in B cell NHL

Forty Seven Inc. (Menlo Park, Calif.) reported data from 22 evaluable patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) in the Phase Ib portion of a Phase Ib/II trial showing that Hu5F9-G4 plus...
18:54 , Apr 20, 2018 |  BC Week In Review  |  Financial News

Surface raises $108M in IPO, $11.5M in private placement

Surface Oncology Inc. (NASDAQ:SURF) raised $108 million through the sale of 7.2 million shares at $15 in an IPO on April 19 underwritten by Goldman Sachs, Cowen and Evercore. In a concurrent private placement, Surface...
16:26 , Apr 19, 2018 |  BC Extra  |  Financial News

Surface slips in first trading day

Surface Oncology Inc. (NASDAQ:SURF) dipped $1.67 (11%) to $13.33 on Thursday after raising $108 million through the sale of 7.2 million shares at $15 in an IPO underwritten by Goldman Sachs, Cowen and Evercore. In...
14:43 , Apr 6, 2018 |  BC Week In Review  |  Company News

Boehringer in-licenses anti-SIRPA checkpoint inhibitor

Boehringer Ingelheim GmbH (Ingelheim, Germany) acquired exclusive, global rights from OSE Immunotherapeutics S.A. (Euronext:OSE) to develop and commercialize OSE-172 (Effi-Dem), a second-generation checkpoint inhibitor. OSE-172 is designed to block the “don’t eat me” signal of CD47...